Home Featured Page 235

Featured

Latest

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

January 2026 Psychedelic Bill Round-up

The Psychedelic News Feed: January 19 – 25, 2025

Whole-Body Effects of Psychedelics Part 2 – Blood and Immune System

Psyched Wellness Submits Applications for Four Further Provisional Patents Surrounding Its...

PT258 – Manesh Girn – Psychedelics and the Brain: Neuroplasticity and...

Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose...

Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and...

MindMed Joins Critical Path Institute’s Patient-Reported Outcome Consortium

Mydecine Reports Second Quarter 2021 Financial Results and Provides Business Update

Field Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results

Filament Health Announces Q2 2021 Financial Results

PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of...

1...234235236...307 Page 235 of 307

EDITOR PICKS

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

January 2026 Psychedelic Bill Round-up

The Psychedelic News Feed: January 19 – 25, 2025

Whole-Body Effects of Psychedelics Part 2 – Blood and Immune System

Psyched Wellness Submits Applications for Four Further Provisional Patents Surrounding Its...

PT258 – Manesh Girn – Psychedelics and the Brain: Neuroplasticity and...

Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose...

Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and...

MindMed Joins Critical Path Institute’s Patient-Reported Outcome Consortium

Mydecine Reports Second Quarter 2021 Financial Results and Provides Business Update

Field Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results

Filament Health Announces Q2 2021 Financial Results

PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of...

EDITOR PICKS

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY